Spero Therapeutics Inc (SPRO)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including...

Form 8-K - Current report

Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary...

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities